Skip to main content

Advertisement

SpringerLink
Log in

Phase II trial of echinomycin in advanced soft tissue sarcomas

A Southwest Oncology Group study

  • Clinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Thirty-four patients with advanced soft tissue sarcomas were entered in a phase II trial of echinomycin. Patients received 1.2 mg/m2 intravenously (i.v.) weekly times four followed by a two week rest period. There were no objective responses. Dose limiting toxicity was gastrointestinal. Echinomycin given on this weekly schedule is inactive in treating previously treated patients with advanced soft tissue sarcomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Corbaz R, Ettlinger L, Gaumann E, Keeler-Schierlein W, Kradolfer F, Neipp L, Prelog V, Reusser P, Zahner H: [Metabolic products of actinomycetes. VII. Echinomycin] Helv Chim Acta 40:199–204, 1957

    Google Scholar 

  2. Huang CH, Mirabelli CK, Mong S, Crooke ST: Intermolecular cross-linking of DNA through bifunctional intercalation of an antitumor antibiotic, luzopeptin A (BBM-928A). Cancer Res 43:2718–2724, 1983

    Google Scholar 

  3. Clinical Brochure for Echinomycin, August 1982. Division of Cancer Treatment, National Cancer Institute

  4. Harvey JH, McFadden M, Andrews WG, Byrne P J, Ahlgren JD, Woolley PV: Phase I study of Echinomycin administered on an intermittent bolus schedule. Cancer Treat Rep 69:1365–1368, 1985

    Google Scholar 

  5. Pazdur R, Haas CD, Baker LH, Leichman CG, Decker D: Phase I study of echinomycin. Cancer Treat Rep 71:1217–1219, 1987

    Google Scholar 

  6. Taylor S, Slavik M, Stephens R, Sayre R: Phase I trial of Echinomycin (Ech) (NSC 526417) daily ×5 schedule. (Abstract/Presentation) Proc Fourth NCI-EORTC Symposium on New Drugs in Cancer Therapy 51, 1983

Download references

Author information

Authors and Affiliations

  1. University of Kansas Medical Center, Kansas City, KS, USA

    Sarah A. Taylor

  2. Southwest Oncology Group Statistical Center, Seattle, WA, USA

    Barbara Metch

  3. Ohio State University Health Center, Columbus, OH, USA

    Stanley P. Balcerzak

  4. Midwest Community Clinical Oncology Program, Kansas City, MO, USA

    Karl H. Hanson

Authors
  1. Sarah A. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara Metch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stanley P. Balcerzak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Karl H. Hanson
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Southwest Oncology Group (SWOG-8505), Operations Office, 5430 Fredericksburg Road, Suite #618, San Antonio, TX 78229-6197, USA

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taylor, S.A., Metch, B., Balcerzak, S.P. et al. Phase II trial of echinomycin in advanced soft tissue sarcomas. Invest New Drugs 8, 381–383 (1990). https://doi.org/10.1007/BF00198595

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00198595

Key words

Search

Navigation